• 1
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 148091.
  • 2
    Whitehead WE, Crowell MD, Bosmajian L, et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology 1990; 98: 33640.
  • 3
    Taub E, Cuevas JL, Cook EW III, Crowell M, Whitehead WE. Irritable bowel syndrome defined by factor analysis Gender and race comparisons. Dig Dis Sci 1995; 40: 264755.
  • 4
    Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol 2008; 103(10): 253643.
  • 5
    Spiegel BM, Gralnek IM, Bolus R, et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004; 164: 177380.
  • 6
    Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005; 3: 71725.
  • 7
    Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007; 5: 53440.
  • 8
    Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 14958.
  • 9
    Spiegel BMR, Harris LA, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF cohort. Am J Gastroenterol 2009; 104: 198491.
  • 10
    Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113: 919.
  • 11
    Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395402.
  • 12
    Drossman DA, Li Z, Toner BB, et al. Functional bowel disorders a multicenter comparison of health status and development of illness severity index. Dig Dis Sci 1995; 40: 98695.
  • 13
    Spiegel BMR, Naliboff BD, Mayer E, Bolus R, Chang L. Development and initial validation of a concise point-of-care IBS severity index: the 4-item “BEST” questionnaire. Gastroenterology 2006; 130: S1040.
  • 14
    Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 40011.
  • 15
    Lackner JM, Gudleski GD, Zack MM, et al. Measuring health-related quality of life in patients with irritable bowel syndrome: can less be more? Psychosom Med 2006; 68: 31220.
  • 16
    Reilly MC, Bracco A, Ricci JF, Santoro J, Stevens T. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire – irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther 2004; 20: 45967.
  • 17
    Labus JS, Bolus R, Chang L, et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther 2004; 20: 8997.
  • 18
    Labus JS, Mayer EA, Chang L, Bolus R, Naliboff BD. The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med 2007; 69: 8998.
  • 19
    Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122: 114056.
  • 20
    Burke LB, Kennedy DL, Miskala PH, Papadopoulos EJ, Trentacosti AM. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther 2008; 84: 2813.
  • 21
    Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 37183.
  • 22
    Drossman D, Morris CB, Hu Y, et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007; 102: 144253.
  • 23
    Whitehead WE, Palsson OS, Levy RL, Feld AD, VonKorff M, Turner M. Reports of “satisfactory relief” by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006; 101: 105765.
  • 24
    Ameen VZ, Heath AT, Mcsorley D, Spiegel BM, Chang L. Global measure of adequate relief predicts clinically important difference in pain and is independent of baseline pain severity in IBS. Gastroenterology 2007; 132: A140.
  • 25
    Leventer SM, Raudibaugh K, Frissora CL, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008; 27: 197206.
  • 26
    Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30: 97485.
  • 27
    Kruis W, Thieme C, Weinzierl M, Schussler P, Holl J, Paulus W. A diagnostic score for the irritable bowel syndrome its value in the exclusion of organic disease. Gastroenterology 1984; 87: 17.
  • 28
    Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 6534.
  • 29
    Drossman DA, Richter JE, Talley NJ. The functional gastrointestinal disorders, pathophysiology, and treatment: a multinational consensus. Little Brown, 1994.
  • 30
    Spiegel BMR, Harris L, Lucak S, et al. Predictors of work productivity in irritable bowel syndrome (IBS): results from the PROOF cohort. Gastroenterology 2008; 134: AB157.
  • 31
    Bond B, Quinlan J, Dukes GE, Mearin F, Clouse RE, Alpers DH. Irritable bowel syndrome: more than abdominal pain and bowel habit abnormalities. Clin Gastroenterol Hepatol 2009; 7: 739.
  • 32
    Lackner JM, Jaccard J, Krasner SS, Katz LA, Gudleski GD, Holroyd K. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol 2008; 6: 899906.
  • 33
    Spiegel BMR, Bolus R, Camilleri M. Impact of baseline severity on the performance of IBS clinical trial endpoints: results of the Rome Endpoints Working Group Meta-Analysis. Gastroenterology 2009. DDW Abstract; in press.
  • 34
    Irvine JE, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. In: DrossmanD, ed. Rome III: The Functional Gastrointestinal Disorders, Third Edition. Lawrence, KS: Allen Press, 2006: 779834.
  • 35
    Spiegel BMR, Harris LA, Lucak S, et al. Measuring IBS patient reported outcomes with a Single Item Numeric Rating Scale: results from the PROOF cohort. Gastroenterology 2008; 134: AB1026.
  • 36
    EuroQOL Group. EuroQol-a new facility for the measurement of health-related quality of life The EuroQol Group. Health Policy 1990; 16: 199208.
  • 37
    Spiegel BM, Kanwal F, Naliboff B, Mayer E. The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100: 226273.